-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NsjA0JMI+U8Z4flFttAcNuGX/LmmBTaPKEbebdMtOWfLdyAjz50U6NVNjKUEMZqW yywNRYVVYp+3ttnkZw6Jwg== 0001036050-99-000552.txt : 19990325 0001036050-99-000552.hdr.sgml : 19990325 ACCESSION NUMBER: 0001036050-99-000552 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 19990315 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 19990323 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON LIFE SCIENCES INC /DE CENTRAL INDEX KEY: 0000094784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870277826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-06533 FILM NUMBER: 99570330 BUSINESS ADDRESS: STREET 1: 31 NEWBURY ST STREET 2: SUITE 300 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6174250200 MAIL ADDRESS: STREET 1: 31 NEWBURY STREET STREET 2: SUITE 300 CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: GREENWICH PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: STRATEGIC MEDICAL RESEARCH CORP /DE DATE OF NAME CHANGE: 19790521 8-K 1 BOSTON LIFE SCIENCES, INC. FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported) March 15, 1999 -------------- BOSTON LIFE SCIENCES, INC. ------------------------------------ (Exact name of registrant as specified in its charter)
Delaware 0-6533 87-0277826 - -------------------------------- ------ ------------------------------------ (State or other jurisdiction of (Commission (I.R.S. Employer Identification No.) incorporation or organization) File No.)
31 Newbury Street, Suite 300 Boston, Massachusetts 02116 - ------------------------------------------- ----------- (Address of principal executive offices) Zip Code Registrant's telephone number, including area code (617) 425-0200 --------------- Item 5. Other Events. ------------ On March 15, 1999 the Company announced that twice-weekly, relatively low dosages of its anti-angiogenic protein, Troponin I, significantly suppressed experimental lung metastases in a rigorous animal model of metastatic melanoma. These results and other findings related to the discovery of the anti-angiogenic properties of Troponin I were published in the March 16, 1999 edition of the Proceedings of the National Academy of Sciences (PNAS). The study, designed to determine the initial dosing schedule for human clinical trials, involved 300 animals and demonstrated that 1mg/kg of Troponin administered twice-weekly suppressed the majority of lung metastases from intravenously injected melanoma. The Company believes that such a relatively modest dosing regimen could prove both practical and convenient for patients and also have a very positive impact on manufacturing and cost issues. On March 16, 1999 the Company issued a statement to reiterate that the Company owns the exclusive license to the U.S. patent on the use of Troponin I to treat a broad spectrum of angiogenic diseases, including, but not limited to, solid tumors, eye diseases and arthritis. Item 7. Exhibits. -------- The following Exhibits are filed as part of this report on Form 8-K: 99.1 Press Release, dated March 15, 1999. 99.2 Press Release, dated March 16, 1999. 1 SIGNATURES - ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto authorized. BOSTON LIFE SCIENCES, INC. Dated: March 22, 1999 By: /s/Joseph Hernon ---------------- Joseph Hernon Chief Financial Officer 2 BOSTON LIFE SCIENCES, INC. CURRENT REPORT ON FORM 8-K EXHIBIT INDEX Exhibit No. Page(s) - ----------- ------- 99.1 Press Release, dated March 15, 1999 4, 5 99.2 Press Release, dated March 16, 1999 6 3 EX-99.1 2 PRESS RELEASE, DATED 03/15/99 Exhibit 99.1
Contacts: Media Contact Analyst Contact Boston Life Sciences, Inc. Jim Weinrebe or Lloyd Benson Neil Berkman Marc E. Lanser, MD Schwartz Communications Berkman Associates Chief Scientific Officer 781-684-0770 310-277-5162 617-425-0200
TWICE-WEEKLY ADMINISTERED ANTI-ANGIOGENIC TROPONIN SHOWS UNUSUALLY POTENT EFFECT IN SUPPRESSION OF EXPERIMENTAL TUMOR METASTASES Report in Proceedings of the National Academy of Sciences March 15 (5:15 pm), 1999, Boston, Mass.--Boston Life Sciences, Inc. (NASDAQ: BLSI) announced that twice-weekly, relatively low dosages of its anti-angiogenic protein, Troponin I, which had previously been shown to inhibit primary cancers in animals, significantly suppressed experimental lung metastases in a rigorous animal model of metastatic melanoma. These results, as well as other scientific findings related to the discovery of the anti-angiogenic properties of Troponin I, are to be published tomorrow in the Proceedings of the National Academy of Sciences (PNAS). The extensive dose-ranging study, which involved 300 animals and was conducted at a leading independent research laboratory specializing in experimental oncology, was designed to determine the initial dosing schedule for human clinical trials. The data demonstrated that 1mg/kg of Troponin administered twice-weekly suppressed the majority of lung metastases from intravenously injected melanoma. The report in PNAS, entitled "Troponin I is Present in Human Cartilage and Inhibits Angiogenesis," was authored by Moses et al from Children's Hospital, Beth Israel Deaconess Medical Center and MIT in Massachusetts. The manuscript was communicated by Robert Langer, professor of Biochemical Engineering, MIT, and member of the National Academy of Sciences. "Both the in vitro and animal data support our view that Troponin is an unusually potent, naturally occurring anti-angiogenic factor," said Marc E. Lanser, MD, chief scientific officer of BLSI. "The fact that doses as little as 1mg/kg given twice-weekly suppressed the majority of melanoma lung metastases is highly significant in that this quantity appears to be significantly lower than the amount required by most other established anti-angiogenic factors to achieve the same degree of suppression achieved in this very difficult model." Lanser continued, "If conventional extrapolation from mouse to human dosing were to ultimately hold true, between 5 and 50mg of Troponin given twice-weekly per patient could potentially be found appropriate for use in human cancer therapy aimed at control of metastatic cancer. Such a relatively modest dosing regimen could prove not only quite practical and convenient for patients, but would also have a very positive impact on manufacturing and cost issues." "The company believes that this publication in one of the most prestigious, peer-reviewed scientific journals in the world delineates the scientific basis for our enthusiasm for Troponin as a potentially important anti-angiogenic product for the treatment and prevention of solid tumor metastases in human cancer therapy," stated David Hillson, president and CEO of BLSI. "We are very gratified that this program, which was one of the very first in anti- angiogenesis, has now achieved this significant recognition and we look forward to initiating human clinical trials, hopefully later this year." more 4 Boston Life Sciences, Inc. Publication in Proceedings of the National Academy of Sciences Page 2 Founded in 1992 by Dr. Marc Lanser, Boston Life Sciences, Inc. is a biotechnology company engaged in the development and commercialization of novel therapeutic and diagnostic compounds that have significant market potential. Compounds awaiting FDA review, in clinical trials or in preclinical development include Therafectin for the treatment of Rheumatoid Arthritis; Altropane(TM), a radiopharmaceutical-imaging agent for the detection of Parkinson's Disease; Troponin, an anti-angiogenic protein for the prevention and treatment of solid tumor metastases; Axogenesis Factor I (AF-1) for the treatment of stroke and spinal cord injury; and small molecule inhibitors to Cmaf and NIP45 for the treatment of allergies and asthma. # # # Statements made in this press release that are not historical facts include forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include uncertainties associated with the results of human clinical trials, regulatory approval processes and other factors. The foregoing contains forward-looking statements with regard to product development, which may not be realized due to the uncertainties inherent in the research and development process, including applying laboratory results to the design and completion of clinical trials as well as the previously mentioned uncertainties. 5 EX-99.2 3 PRESS RELEASE, DATED 03/16/99 Exhibit 99.2 FOR IMMEDIATE RELEASE BOSTON LIFE SCIENCES INC. REITERATES ITS EXCLUSIVE PATENT POSITION ON THE USE OF TROPONIN I March 16, 1999, Boston, Mass.--In the wake of a misleading television report, Boston Life Sciences, Inc. (NASDAQ: BLSI) reiterates that the Company owns the exclusive license to the recently issued (November 1998) U.S. patent on the use of Troponin I to treat a broad spectrum of angiogenic diseases, including solid tumors, eye diseases, atherosclerosis, hypertrophic scarring (including in the spinal cord), arthritis and psoriasis. Boston Life Sciences Inc. announced yesterday that twice-weekly, relatively low dosages of its anti-angiogenic protein, Troponin I, which had previously been shown to inhibit primary cancers in animals, significantly suppressed experimental lung metastases in a rigorous animal model of metastatic melanoma. These results, as well as other scientific findings related to the discovery of the anti-angiogenic properties of Troponin I, were published today in the Proceedings of the National Academy of Sciences (PNAS). # # # 6 -----END PRIVACY-ENHANCED MESSAGE-----